Key result
High-probability HFpEF linked to ~46% higher post-liver transplantation mortality in end-stage liver disease.
Why the study?
Heart failure with preserved ejection fraction and its risk factors are increasingly recognized in end-stage liver disease, but its characteristics, risk factors, and prognostic impact on post-liver transplantation mortality needed investigation.
Does high-probability HFpEF increase post-liver transplantation mortality in patients with end-stage liver disease?
Cohort (n=3,244)
No
Does high-probability HFpEF increase post-liver transplantation mortality in patients with end-stage liver disease?
Hazard Ratio: 1.46 (95% CI 1.08–1.98)
p-value: p=0.013
High-probability HFpEF is present in 6.6% of ESLD patients and is associated with poorer long-term survival after liver transplantation, particularly in those with advanced liver disease.
Heart failure with preserved ejection fraction (HFpEF) and its risk factors are increasingly recognized in patients with end-stage liver disease (ESLD). The aim of this study was to characterize HFpEF and identify relevant risk factors in patients with ESLD. Additionally, the prognostic impact of high-probability HFpEF on post–liver transplantation (LT) mortality was investigated. Patients with ESLD prospectively enrolled from the Asan LT Registry between 2008 and 2019 were divided into groups with low (scores of 0 and 1), intermediate (scores of 2-4), and high (scores of 5 and 6) probability using the Heart Failure Association–PEFF diagnostic score for HFpEF. Gradient-boosted modeling in machine learning was further used to appraise the apparent importance of risk factors. Finally, post-LT all-cause mortality was followed for 12.8 years (median 5.3 years); there were 498 deaths after LT. Among the 3,244 patients, 215 belonged to the high-probability group, commonly those with advanced age, female sex, anemia, dyslipidemia, renal dysfunction, and hypertension. The highest risk factors for the high-probability group, according to gradient-boosted modeling, were female sex, anemia, hypertension, dyslipidemia, and age >65 years. Among patients with Model for End-Stage Liver Disease scores of >30, those with high, intermediate, and low probability had cumulative overall survival rates of 71.6%, 82.2%, and 88.9% at 1 year and 54.8%, 72.1%, and 88.9% at 12 years after LT (log-rank P = 0.026), respectively. High-probability HFpEF was found in 6.6% of patients with ESLD with poorer long-term post-LT survival, especially those with advanced stages of liver disease. Therefore, identifying HFpEF using the Heart Failure Association–PEFF score and addressing modifiable risk factors can improve post-LT survival.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2023) conducted a cohort in End-stage liver disease (ESLD) undergoing liver transplantation (n=3,244). High-probability HFpEF (HFA-PEFF score 5-6) vs. Low- and intermediate-probability HFpEF (HFA-PEFF score 0-4) was evaluated on Cumulative all-cause mortality at 12 years (HR 1.46, 95% CI 1.08-1.98, p=0.013). High-probability HFpEF in patients with end-stage liver disease increased the risk of all-cause mortality after liver transplantation by 46% compared to lower probability groups (HR 1.46).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: